Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Cohort 1:
Participants who have diagnosed with unresectable stage IIIB/IIIC/IV NSCLC
Participants who have been diagnosed six months before the start of the study were required to have two complete tumor assessments within at least 6 months intervals after the diagnosis
Participants who were newly diagnosed within six months before the start of the study were required to have complete baseline information (see section 6.4.1)
Participants who have received standard first-line treatment defined by guideline CSCO (https://www.csco.org.cn/cn/index.aspx) and NCCN (https://www.nccn.org/)
Cohort 2:
Participants who are newly diagnosed with unresectable Stage IIIB/IIIC/IV NSCLC after the start of the study
Participants who are able to be followed up by the participating site
Participants planned to receive first line anti-cancer treatment targeting unresectable stage IIIB/IIIC/IV NSCLC in the study site after study initiation
You may not be if
Participants who have received prior systematic treatment for unresectable Stage IIIB/IIIC/IV NSCLC
Participants who have participated in any anti-cancer, regimen-specified clinical study of first-line treatment for unresectable Stage IIIB/IIIC/IV NSCLC
